Shares of KP Tissue Inc. (TSE:KPT – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$8.46 and traded as high as C$8.50. KP Tissue shares last traded at C$8.45, with a volume of 23,348 shares.
Wall Street Analyst Weigh In
Separately, TD Securities boosted their price target on KP Tissue from C$8.50 to C$9.00 and gave the company a “hold” rating in a report on Wednesday, August 14th.
Read Our Latest Stock Report on KPT
KP Tissue Price Performance
KP Tissue (TSE:KPT – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported C$0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.22 by C($0.10). The business had revenue of C$509.80 million for the quarter, compared to analysts’ expectations of C$487.50 million. As a group, analysts forecast that KP Tissue Inc. will post 0.4400207 EPS for the current fiscal year.
KP Tissue Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, October 15th will be given a dividend of $0.18 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $0.72 annualized dividend and a yield of 8.52%. KP Tissue’s dividend payout ratio (DPR) is presently 120.00%.
KP Tissue Company Profile
KP Tissue Inc, through its interest in Kruger Products L.P., produces, distributes, markets, and sells a range of disposable tissue products in Canada and the United States. The company operates through two segments, Consumer and Away-From-Home. It offers bathroom and facial tissues, paper towels, and napkins.
See Also
- Five stocks we like better than KP Tissue
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- The 3 Best Fintech Stocks to Buy Now
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Investing in Travel Stocks Benefits
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for KP Tissue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KP Tissue and related companies with MarketBeat.com's FREE daily email newsletter.